Compare Crispr Therapeutics AG (CRSP) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Lockheed Martin Corporation — how do they compare? Crispr Therapeutics AG trades at $49.94 (market cap $4.97B), while Lockheed Martin Corporation trades at $517.05 (market cap $118.74B). The key difference: Lockheed Martin Corporation is far larger — about 23.9× Crispr Therapeutics AG's market cap, and Lockheed Martin Corporation pays a 2.68% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LMT | |
|---|---|---|
Market Cap | $4.97B | $118.74B |
Sector | Health | Industrials |
52-Week High | $76.78 | $676.70 |
52-Week Low | $44.34 | $410.74 |
Enterprise Value | $3.32B | $137.54B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Lockheed Martin (LMT) trades at $520.68, down 0.49% on the day, with a bearish technical signal and mixed earnings history. The company reported $75.05B in 2025 revenue and a net income margin of 6.38%, while maintaining a $194B backlog as of Q4 2025 (24/7 Wall Street, 2026-07-13). Analyst consensus is bullish with a $614 price target, supported by strong defense spending trends.
Outlook remains positive due to robust demand from global defense budgets, but risks include execution challenges and margin pressure. The stock offers value with a P/E of 25.21 and dividend yield near 2.66%, though recent EPS misses warrant caution. Institutional sentiment favors long-term growth amid geopolitical tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
